PARIS--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced the availability of its Dexcom ONE real-time ...
The growth stock is outpacing the S&P 500 thanks to its foothold in the market for diabetes management. Dexcom has consistently surpassed the S&P 500's performance this year, experiencing substantial ...
More than 34 million Americans have diabetes and an additional 88 million are at risk of developing the disease, according to the American Diabetes Association. In this world of data, automation, and ...
In a bid to fortify its foothold in the Type 2 diabetes space, DexCom, Inc. DXCM recently announced a new amendment to its license deal with Verily, the life sciences unit of Alphabet GOOGL. With this ...
DexCom, Inc. DXCM is scheduled to release third-quarter 2020 results on Oct 27, after the closing bell. In the last reported quarter, the company delivered an earnings surprise of 154.8%. Further, it ...
DexCom’s stock (NASDAQ: DXCM) trades at $397 currently and it has gained 80% in value so far this year. It traded at a pre-Covid high of $302 in February, and it is currently 30% higher than that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback